Tirzepatide

Also known as: Mounjaro, Zepbound

Dual GIP/GLP-1 receptor agonist: greater weight loss than GLP-1 alone.

Typical dose

2.5 mg – 15 mg

Frequency

once weekly

Route

Subcutaneous

Half-life

5 days

Routes

Subcutaneous

Status

FDA-approved (Mounjaro for T2D, Zepbound for weight management)

Benefits

• Superior weight loss vs semaglutide
• Blood sugar control
• Reduced appetite

Dosing

A common research range for Tirzepatide is 2.5 mg to 15 mg once weekly. Titrate: 2.5mg x4wk → 5mg x4wk → 7.5mg → 10mg → 12.5mg → 15mg. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.

Half-life

Tirzepatide has an approximate half-life of 5 days. Vial plots the real concentration curve from your logged doses so you can see peak windows and when levels taper.

Storage

2-8°C; room temp up to 21 days.

Reported side effects

• Nausea
• Diarrhea
• Decreased appetite
• Vomiting
• Constipation

Contraindications

• Personal/family history of MTC
• MEN 2 syndrome

Track Tirzepatide with Vial

Vial logs every Tirzepatide dose, plots its half-life curve, calculates reconstitution math, and keeps your whole protocol on schedule — on-device and private. Download Vial on the App Store →

This page is for educational and harm-reduction purposes only. Tirzepatide is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.